Skip to main content
. 2020 Jan 1;10(3):1262–1280. doi: 10.7150/thno.38834

Figure 5.

Figure 5

Application and strategy of nanocarrier-mediated antioxidant therapy in liver cancer: combined with radiotherapy and chemotherapy to reduce the side effects. (A) Nanocarriers can be designed to be passively or actively targeting tumor site. (B) Enrichment in tumor site increases tumor/organ ratio, thereby reducing the side effects of systemic intravenous chemotherapy (e.g., gastrointestinal reactions and hematopoietic disorders, (C).